| |
|
New proposals from the research-based pharmaceutical industry should reduce inequalities in patient access to medicines across Europe
|
|
|
The new pledge from EFPIA member companies should drastically increase the availability of innovative medicines in EU countries and decrease the time patients must wait for new medicines by several months.
EFPIA member companies commit to file for pricing and reimbursement in all EU countries as soon as possible and no later than 2 years from the central EU market authorisation, provided that local systems allow it. The commitment is designed to help deliver faster, more equitable access to medicines for patients across Europe.
Read more
|
|
|
|
